LSL Pharma Group Inc
XTSX:LSL
Income Statement
Earnings Waterfall
LSL Pharma Group Inc
Income Statement
LSL Pharma Group Inc
| Jul-2011 | Oct-2011 | Jan-2012 | Apr-2012 | Jul-2012 | Oct-2012 | Jan-2013 | Apr-2013 | Mar-2022 | Jun-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
3
+76%
|
3
+5%
|
4
+18%
|
7
+62%
|
10
+53%
|
12
+21%
|
14
+18%
|
16
+10%
|
18
+12%
|
20
+14%
|
23
+15%
|
27
+15%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(4)
|
(3)
|
(3)
|
(5)
|
(8)
|
(10)
|
(11)
|
(12)
|
(12)
|
(14)
|
(16)
|
(19)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(1)
N/A
|
(1)
-51%
|
0
N/A
|
1
+1 700%
|
2
+43%
|
2
+6%
|
2
+46%
|
3
+35%
|
4
+22%
|
5
+35%
|
6
+18%
|
7
+8%
|
8
+17%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(0)
|
(0)
|
(0)
|
(0)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(3)
|
(2)
|
(2)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(0)
|
(1)
|
(6)
|
|
| Selling, General & Administrative |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(6)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
(0)
|
(2)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
0
|
|
| Operating Income |
(0)
N/A
|
(0)
-56%
|
(0)
-186%
|
(0)
-3%
|
(2)
-359%
|
(2)
+2%
|
(2)
+10%
|
(2)
+2%
|
(2)
-14%
|
(4)
-89%
|
(2)
+45%
|
(1)
+52%
|
(1)
-36%
|
(2)
-58%
|
(2)
+20%
|
(1)
+62%
|
(0)
+68%
|
1
N/A
|
6
+623%
|
6
+1%
|
2
-74%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
(2)
|
(2)
|
(2)
|
(3)
|
0
|
(0)
|
(0)
|
5
|
0
|
0
|
4
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(3)
|
(3)
|
(2)
|
(1)
|
0
|
0
|
(1)
|
(1)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(0)
N/A
|
(0)
-56%
|
(0)
-186%
|
(0)
-3%
|
(2)
-359%
|
(2)
+2%
|
(2)
+10%
|
(2)
+2%
|
(2)
-37%
|
(4)
-60%
|
(5)
-53%
|
(7)
-32%
|
(8)
-11%
|
(8)
-6%
|
(5)
+45%
|
(2)
+56%
|
(2)
+18%
|
3
N/A
|
3
+3%
|
4
+4%
|
3
-22%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(0)
|
(0)
|
(0)
|
(0)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(4)
|
(5)
|
(7)
|
(8)
|
(8)
|
(5)
|
(2)
|
(2)
|
3
|
3
|
4
|
3
|
|
| Net Income (Common) |
(0)
N/A
|
(0)
-56%
|
(0)
-186%
|
(0)
N/A
|
(2)
-358%
|
(2)
+1%
|
(2)
+10%
|
(2)
+2%
|
(2)
-40%
|
(4)
-60%
|
(5)
-53%
|
(7)
-32%
|
(8)
-11%
|
(8)
-6%
|
(5)
+45%
|
(2)
+56%
|
(2)
+18%
|
3
N/A
|
3
+4%
|
4
+4%
|
3
-22%
|
|
| EPS (Diluted) |
-0.57
N/A
|
-1.75
-207%
|
-0.55
+69%
|
-0.81
-47%
|
-3.81
-370%
|
-2.82
+26%
|
-2.43
+14%
|
-2.38
+2%
|
-0.03
+99%
|
-0.05
-67%
|
-0.08
-60%
|
-0.1
-25%
|
-0.11
-10%
|
-0.11
N/A
|
-0.06
+45%
|
-0.02
+67%
|
-0.01
+50%
|
0.03
N/A
|
0.04
+33%
|
0.03
-25%
|
0.02
-33%
|
|